OTC Markets EXMKT - Delayed Quote USD
Innoveren Scientific Inc. (IVRN)
0.0002
0.0000
(0.00%)
At close: April 28 at 4:00:00 PM EDT
Breakdown
TTM
12/31/2022
12/31/2021
12/31/2020
Total Revenue
--
453.4600
1,611.5180
2,150.6720
Cost of Revenue
0.9990
117.6010
704.7050
766.9570
Gross Profit
-0.9990
335.8590
906.8130
1,383.7150
Operating Expense
2,088.3500
3,393.8180
6,099.6140
8,476.0590
Operating Income
-2,089.3490
-3,057.9590
-5,192.8010
-7,092.3440
Net Non Operating Interest Income Expense
-434.8310
139.8050
-176.8360
-1,462.7500
Other Income Expense
-734.4230
-7,381.4260
570.3300
2,095.8580
Pretax Income
-3,258.6030
-10,299.5800
-4,799.3070
-6,459.2360
Net Income Common Stockholders
-3,258.6030
-10,299.5800
-4,799.3070
-6,781.4110
Diluted NI Available to Com Stockholders
-3,258.6030
-10,299.5800
-4,799.3070
-6,781.4110
Basic EPS
-3.68
-35.06
-32.93
-60.00
Diluted EPS
-3.68
-35.06
-32.93
-60.00
Basic Average Shares
591.7530
293.7780
145.7360
111.4910
Diluted Average Shares
591.7530
293.7780
145.7360
111.4910
Total Operating Income as Reported
-2,881.6050
-5,105.7730
-5,285.6040
-7,092.3440
Total Expenses
2,089.3490
3,511.4190
6,804.3190
9,243.0160
Net Income from Continuing & Discontinued Operation
-3,258.6030
-10,299.5800
-4,799.3070
-6,459.2360
Normalized Income
-2,602.9750
-6,055.6660
-5,405.3240
-8,641.9100
Interest Income
3.0900
507.9440
--
--
Interest Expense
437.9210
368.1390
176.8360
1,462.7500
Net Interest Income
-434.8310
139.8050
-176.8360
-1,462.7500
EBIT
-2,820.6820
-9,931.4410
-4,622.4710
-4,996.4860
EBITDA
-2,811.6840
-9,917.2260
-4,606.6420
-4,915.0160
Reconciled Cost of Revenue
0.9990
117.6010
704.7050
766.9570
Reconciled Depreciation
8.9980
14.2150
15.8290
81.4700
Net Income from Continuing Operation Net Minority Interest
-3,258.6030
-10,299.5800
-4,799.3070
-6,459.2360
Total Unusual Items Excluding Goodwill
-655.6280
-4,243.9140
606.0170
2,182.6740
Total Unusual Items
-655.6280
-4,243.9140
606.0170
2,182.6740
Normalized EBITDA
-2,156.0560
-5,673.3120
-5,212.6590
-7,097.6900
12/31/2020 - 12/19/2014
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
NBCO Neon Bloom, Inc.
0.0121
0.00%
MYMX Mymetics Corporation
0.0003
0.00%
SPPH Spencer Pharmaceutical Inc.
0.0001
0.00%
MRPI Mera Pharmaceuticals, Inc.
0.0001
0.00%
BSSP Baseline Productions, Inc.
0.0001
0.00%
DNAG DNAPrint Genomics, Inc.
0.0000
0.00%
GSTC GlobeStar Therapeutics Corporation
0.0001
0.00%
INTI Inhibitor Therapeutics, Inc.
0.0500
0.00%
AIBT Aibotics Inc.
0.0220
0.00%
RSPI RespireRx Pharmaceuticals Inc.
0.0020
-4.76%